ERBB2 and breast cancer: MRI demonstrated a higher sensitivity and NPV than US among all tumors (sensitivity 0.89 vs 0.74; NPV 0.92 vs 0.83) and in HR+/HER2+ (sensitivity 0.93 vs 0.69; NPV 0.9 vs 0.77) and HR−/HER2+ BC (sensitivity 1 vs 0.82; NPV 1 vs 0.91).